Hannah Joseph Hospital claims to have a strong focus on neurosciences, covering neurosurgery, neurology, and neurointerventional radiology. It states that it handles complex brain and spinal procedures and undertakes minimally invasive neurological interventions such as aneurysm coiling and stroke-related procedures.
The hospital claims to offer diagnostic services such as MRI, CT scans, and EEGs for neurological conditions. It also states that it follows defined treatment and rehabilitation protocols for disorders, including epilepsy, stroke, and neurodegenerative diseases.
Hannah Joseph Hospital claims to provide 24/7 emergency services and critical care support. It states that its intensive care units are equipped to manage patients requiring advanced monitoring and ventilatory support through a multidisciplinary approach.
The hospital is empanelled under government health insurance schemes such as TNNHIS and CMCHIS through partnerships with MDIndia Healthcare Services. It claims that this enables it to provide cashless treatment to eligible beneficiaries across various sections of the population in Tamil Nadu.
The company has witnessed a consistent increase in its revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 54.62 crore in FY23 to Rs 63.41 crore in FY24 and Rs 77.53 crore in FY25. PAT increased from Rs 1.01 crore in FY23 to Rs 4.07 crore in FY24 and Rs 7.21 crore in FY25.
Hannah Joseph Hospital’s revenues are significantly dependent on its only hospital in Madurai, and it derives almost all revenue from operations from this single location. Any adverse economic, political, or regional developments in or around Madurai, along with factors such as reduced patient footfall, regulatory changes, reputational harm, medical negligence-related liabilities, adverse publicity, natural calamities, or increased competition, could affect its business, financial condition, and results of operations.
A substantial portion of Hannah Joseph Hospital’s revenue is dependent on neurosciences, interventional neuro-radiology, trauma services, and radiology services. Any adverse change affecting these fields, such as inability to adopt modern technology, competitors implementing newer techniques, decline in new patient registrations, loss of key medical professionals, medical negligence-related liabilities, or regulatory changes, could adversely impact its business, prospects, financial condition, and results of operations.
In-patient admissions accounted for Rs 27.96 crore (65.72 percent) of the company’s revenue for the period ended September 30, 2025; Rs 52.09 crore (67.19 percent) in FY25; Rs 43.53 crore (68.65 percent) in FY24; and Rs 36.86 crore (67.49 percent) in FY23. Any decline in in-patient volumes, such as patients opting for competitors for admissions and treatment, could materially impair revenue growth and adversely affect its financial condition and results of operations.
The top supplier alone accounted for Rs 1.50 crore (20.76 percent) of the company’s total purchase for the period ended September 30, 2025; Rs 2.46 crore (18.75 percent) in FY25; Rs 1.82 crore (19.95 percent) in FY24 and Rs 1.19 crore (14.79 percent) in FY23. Any delay, disruption, or failure by this vendor to deliver products on time or at acceptable prices, or any adverse change in supply terms, could increase procurement costs and adversely affect the company’s business, profitability, and reputation.
The company is involved in certain ongoing legal proceedings. The company’s business prospects could be hit in case of adverse judgments in any of these cases.
As of September 30, 2025, the company had outstanding financial indebtedness of Rs 29.64 crore. Failure to service or repay these loans could harm the company’s operations and financial position.